Myriad Genetics (MYGN) Misses Q4 EPS by 6c; Issues Weak Q1, FY17 Outlook

Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.32, $0.06 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $186.5 million versus the consensus estimate of $187.92 million.

GUIDANCE:

Myriad Genetics sees Q1 2017 EPS of $0.25-$0.27, versus the consensus of $0.43. Myriad Genetics sees Q1 2017 revenue of $167-170 million, versus the consensus of $192.0 million.

Myriad Genetics sees FY2017 EPS of $1.00-$1.10, versus the consensus of $1.65. Myriad Genetics sees FY2017 revenue of $740-760 million, versus the consensus of $755.5 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• Cerebras CEO says investors misunderstood margin guidance
• NXP Semiconductors names Mike Lucarelli as new investor relations head
• Myriad Genetics board member Skovronsky resigns